EU/3/19/2211: Orphan designation for the treatment in haematopoietic stem cell transplantation

besilesomab

Table of contents

Overview

On 17 October 2019, orphan designation EU/3/19/2211 was granted by the European Commission to Therapharm Deutschland GmbH, Germany, for besilesomab for treatment in haematopoietic stem cell transplantation.

The sponsorship was transferred to Advanced Nuclear Medicine Ingredients, Belgium, in October 2021.

Key facts

Active substance
besilesomab
Intented use
Treatment in haematopoietic stem cell transplantation
Orphan designation status
Positive
EU designation number
EU/3/19/2211
Date of designation
17/10/2019
Sponsor

Advanced Nuclear Medicine Ingredients
Rue De Hermee 255
4040 Herstal
Liege
Belgium
Tel. +32 4 378 50 47
E-mail: info@telixpharma.com 

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating